Zevra Therapeutics, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was signed April 1, 2024. Although the request identifies 2023 Q4, this is an annual report; the filing text does not provide a clear standalone fourth-quarter income statement.
Business context
Zevra is a rare-disease biopharmaceutical company with approved products AZSTARYS and OLPRUVA and candidates including arimoclomol, celiprolol, and KP1077. Zevra acquired Acer Therapeutics on November 17, 2023, adding OLPRUVA and celiprolol. The financial statements include Acer from November 18, 2023.
Key financial metrics
| Metric | 2023 | 2022, restated |
|---|---|---|
| Revenue, net | $27.5 million | $10.2 million |
| Cost of revenue | $2.9 million | $0.2 million |
| Research and development | $39.8 million | $19.8 million |
| Selling, general and administrative | $34.3 million | $15.0 million |
| Operating loss | $(49.6) million | $(42.6) million |
| Net loss | $(46.0) million | $(26.8) million |
| Basic and diluted loss per share | $(1.30) | $(0.78) |
| Net cash used in operating activities | $(33.5) million | $(18.7) million |
- Year-end cash and cash equivalents were $43.0 million; securities at fair value were $24.7 million. Together, cash and investments were approximately $67.7 million.
- Total assets were $172.3 million, total liabilities $110.5 million, and stockholders’ equity $61.9 million. Accumulated deficit was $399.8 million.
- Debt included a $37.7 million Wells Fargo margin loan, classified as current, and a $5.0 million secured Nantahala note. The note’s carrying amount was $5.1 million; principal is due in 2026, with amortization beginning in 2025.
- Warrant liabilities were $16.1 million; contingent value right liabilities were $7.3 million. These are liabilities, not borrowings.
- Revenue included $18.5 million under the AZSTARYS license agreement, including $15.0 million of 2023 sales milestones; $8.7 million of net arimoclomol expanded-access revenue; and $0.2 million under the Corium consulting agreement. OLPRUVA revenue after the acquisition was negligible in 2023.
Material changes versus 2022
- Revenue increased $17.3 million, principally from AZSTARYS milestones and higher arimoclomol expanded-access sales, partly offset by lower Corium consulting revenue.
- Net loss widened by $19.3 million. Operating loss increased $7.0 million as R&D and SG&A rose substantially; the prior year also included $17.7 million of acquired in-process R&D expense.
- Operating cash use increased $14.8 million. Cash and cash equivalents fell from $65.5 million to $43.0 million.
- The Acer acquisition added OLPRUVA, celiprolol, $68.0 million of acquired OLPRUVA intangible assets, and $4.7 million of goodwill. Acer-related consideration included Zevra shares, debt and a contingent value right with potential payments of up to $76 million, subject to milestones.
Outlook, risks and unusual items
- Liquidity and going concern: Management and the auditor report substantial doubt about Zevra’s ability to continue as a going concern. Management estimated existing resources would fund operations into, but not through, 2026. The $37.7 million margin loan may have to be repaid unless restructured; the filing says repayment could create a cash shortfall as early as mid-2024. Additional financing may be needed, with no assurance it will be available on acceptable terms.
- Pipeline milestones: The FDA set a September 21, 2024 PDUFA date for the arimoclomol NDA and intended to discuss it at an advisory committee meeting. The KP1077 idiopathic-hypersomnia Phase 2 trial concluded in March 2024; reported improvements were clinically meaningful but the exploratory trial was not powered for statistical significance. Celiprolol’s Phase 3 trial was ongoing.
- Commercial execution: OLPRUVA’s full U.S. launch began January 29, 2024. Its commercial uptake, payer coverage and reimbursement remain important uncertainties. AZSTARYS milestone revenue is variable; the $10 million milestone earned in Q4 2023 was received in February 2024.
- Restatement and controls: Zevra restated 2022 and specified 2022–2023 interim financial statements after determining certain warrants should have been recorded as liabilities. The 2022 restated net loss was $26.8 million, versus $41.5 million previously reported, largely reflecting noncash warrant fair-value adjustments. Management identified a material weakness in warrant accounting and concluded financial-reporting and disclosure controls were ineffective at year-end 2023. Remediation was underway but not yet considered complete.
- Other risks and contingencies: Risks include dependence on external funding, clinical and regulatory uncertainty, third-party manufacturing and commercialization, competition, and payer access. Acer-related stockholder lawsuits were disclosed; no accrual was recorded, and the company intends to defend them. The filing also records a $12.2 million estimated reserve liability associated with French arimoclomol EAP clawbacks.
Important facts for investors to verify
- Whether the margin loan was restructured, repaid, or otherwise remained a near-term liquidity burden, and the latest cash runway and financing position.
- Arimoclomol’s FDA review outcome, advisory committee proceedings, and any resulting approval, labeling, or commercial-launch requirements.
- OLPRUVA launch performance, payer access, net sales, and the royalties and other obligations payable to Relief and other parties.
- Progress in remediating the material weakness, and whether future filings report effective internal controls.
- The terms, timing, and likelihood of Acer CVR milestones, and the status or potential financial impact of merger-related litigation.